A genetically-engineering bone marrow stem cell therapy for stroke

导读：我们已经报道骨髓细胞移植在脑缺血动物模型中显示出治疗效果。在本研究中，我们将基因工程骨髓干细胞移植到大脑中动脉闭塞模型大鼠体内，研究其潜在的治疗效果。方法：制备5种基因工程骨髓干细胞，1)用hTERT基因永生化干细胞，2)用BDNF基因促进神经营养作用，3)用GDNF基因促进神经营养作用，4)用Ang-1基因促进血管生成作用，5)用P1GF基因促进血管生成作用。采用磁共振成像、光谱学和组织学方法评估病变大小。结果：基因工程骨髓干细胞移植可减少病变体积。病变大小的减少可以通过MRI在体内评估，并与随后的脑部组织学检查相关。结论：高纯度基因工程骨髓干细胞在脑缺血模型中具有神经保护作用和血管特征性。因此，一种高度纯化、扩增和基因工程的骨髓细胞成分已证明对脑缺血有治疗作用。

Introduction : We have reported that transplantation of bone marrow cells has demonstrated therapeutic efficacy in animal models of cerebral ischemia. In the present study, we transplanted genetically-engineering bone marrow stem cells into middle cerebral artery occlusion model rats to study their potential therapeutic benefit.Methdos : We have made five genetically-engineering bone marrow stem cells, 1) to immortalize the stem cells with hTERT gene, 2) to promote the neurotrophic effects with BDNF gene, 3) to promote the neurotrophic effects with GDNF gene, 4) to promote the angiogenetic effects with Ang-1 gene, 5) to promote the angiogenetic effects with P1GF gene. Lesion size was assessed using MR imaging and spectroscopy, and histological methods.Results : Transplantation of genetically-engineering bone marrow stem cells reduced lesion volume. The reduction of lesion size could be assessed in vivo with MRI and was correlated with subsequent histological examination of the brain.Conclusion : This work demonstrates that highly purified genetically-engineering bone marrow stem cells are neuroprotective and angeigenetic in cerebral ischemia models. Thus, a highly purified, expanded, and genetically-engineered cellular component of bone marrow has demonstrated the therapeutic benefits in cerebral ischemia.